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Abstract 
The Coronavirus Disease 2019 (COVID-19) pandemic has infected >5.5 million people globally 
and carries a relatively high mortality rate. Currently, there is no effective vaccine or therapy 
approved for the treatment COVID-19, though many such therapeutics are being evaluated in 
clinical trials. Using the unique profiles of altered gene expression found in NHBE, A549_ACE2 
and Calu3 human lung epithelial cells after Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) infection, we conducted a computational analysis to identify dysfunctional 
signaling pathways within infected cells. Using these data, potential therapeutic targets were 
identified and matched with existing medications to develop a theoretical approach to 
pharmacologic repurposing and inform clinical trial decisions. Specifically, signaling pathways 
upregulated by SARS-CoV-2 infection and their associated gene ontologies (GOs) were extracted 
and clustered to generate 10 super-GOs. The genes associated with the identified signaling 
pathways and the super-GOs were used as gene signatures to identify drugs that can potentially 
inhibit these signaling cascades. In these results, interesting signaling pathways and GOs such 
as JAK-STAT, IRF7-NFkB signaling, and MYD88/CXCR6 immune signaling were identified. Many 
drugs were identified with downstream inhibition of these signaling pathways and GOs, and many 
of which are currently undergoing clinical trial evaluation. The analysis results can be potentially 
helpful to facilitate the future clinical trial design. Rigorous clinical trial and experimental 
validations are needed to validate these results, considering the limitation of pure computational 
data analysis based on the noisy and limited data. some of these drugs might have harmful effects 
and cautions. 
 
 
  
1. Introduction 
By 05-26-2020, there were >1,715,000 confirmed cases (with >100,000 deaths) of COVID-19 in 
the U.S. and >5.5 million cases (with >348,000 deaths) globally, based on the COVID-19 
Dashboard1 operated by the Center for Systems Science and Engineering (CSSE) at Johns 
Hopkins University (JHU) (URL: https://coronavirus.jhu.edu/map.html). The proposed primary site 
of involvement is the lung, which leads to acute hypoxemic respiration and ultimately can lead to 
multi-organ failure and death2. The mortality rate of Coronavirus Disease 2019 (COVID-19) is 
relatively high3. There are no FDA approved drugs for the treatment of COVID-19, but multiple 
are being evaluated through compassionate use programs or in clinical trials and include 
chloroquine and hydroxychloroquine, azithromycin and lopinavir–ritonavir. Similarly, remdesivir, 
developed by Gilead Sciences, has been used on a compassionate basis and is now undergoing 
evaluation through clinical trials with promising preliminary data. Nevertheless, the relatively high 
mortality rate3 and degree of international impact necessitates further therapeutic advancements, 
which can be more rapidly achieved through the repurposing of existing medications.  
While wait for the effective vaccine and novel drugs that will take long time to developed, more 
and more clinical trials treating COVID-19 are being registered in a rapid speed in response to 
the global pandemic. There are about 1,132 clinical trials for COVID-19 treatment by May 26, 
2020, based on the data available from the dashboard4 of real-time clinical trials of COVID-19 
(URL: https://www.covid-trials.org/). However, there is no effective drug that can COVID-19 
effectively. One reason is that most of the current clinical trials are based on limited knowledge of 
the disease and observed phenotypes. Whereas, the molecular mechanisms and dysfunctional 
signaling pathways within the host cells, like lung cells, caused the Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2) infection remain unclear.  
To help the understand the transcriptional variations within lung cells caused by SARS-CoV-
2, Dr. Albrecht and Dr. tenOever’s laboratories released the RNA-seq gene expression profiles of 
human NHBE (Normal Human Bronchial Epithelial) cells, A549 (with no ACE2 expression), 
A549_ACE2 (A549 lung cancer cells transduced with a vector expressing human ACE2), and 
CALU-3 lung cancer cells (with ACE2 expression), and 2 human lung samples infected by SARS-
CoV-25, which greatly facilitates the understanding of the genetic pathways that become 
dysregulated during active infection. More importantly, this allows for the identification of activated 
signaling pathways that can be targeted by existing pharmaceutical agents. Therefore, the 
objective of this study is to develop a systems biology analysis pipeline to identify, in an unbiased 
manner, the activated signaling pathways within lung host cells, and to identify and reposition 
existing therapeutics for COVID-19 treatment, which can be potentially helpful to facilitate the 
experimental screening and clinical trial design. 
  
2. Materials and Methodology 
RNA-seq data (gene expression) from NHBE (Normal Human Bronchial Epithelial) cells, A549 
(with no ACE2 expression), A549_ACE2 (A549 lung cancer cells transduced with a vector 
expressing human ACE2), and CALU-3 lung cancer cells (with ACE2 expression) cells infected 
by SARS-CoV-2 were obtained from GEO (GSE147507)5. This data was generated by Drs. 
Albrecht and tenOever’s at the Icahn School of Medicine at Mount Sinai. The DEseq26 tool was 
used to calculate the fold change and p-value of individual genes in the NHBE (normal), 
A549_ACE2, and CALU-3 lung cancer cells respectively before and after viral exposure. The data 
of A549 cell was not used considering that the ACE2 is not expressed in A549 cell.  
For the signaling network analysis, the 307 KEGG (Kyoto Encyclopedia of Genes and 
Genomes)10 signaling pathways were extracted. To identify the activated signaling network for 
NHBE, A549_ACE2 and CALU-3 respectively, the signaling paths, i.e., the shortest paths link 
source signaling genes (starting genes on the signaling pathways) and the sink signaling genes 
(ending genes on the signaling pathways) within the 307 KEGG signaling pathways were first 
identified. For each signaling path, the average fold change of genes on the signaling path was 
calculated. Then the signaling paths with the average fold change score greater than the mean 
score + 1.25 standard deviation threshold were selected to construct the activated signaling 
network. To remove the tumor specific signaling, the common signaling pathways between NHBE 
and A549_ACE2, and between NHBE and CALU-3 were unified as the potential activated 
signaling pathways caused the viral infection. To identify potential drugs that can inhibit the 
signaling genes on the activated signaling pathways, the drug-target interactions of FDA-
approved drugs were downloaded from the DrugBank13 database. Then drugs targeting the 
activated signaling pathways were identified as potential effective drug candidates for COVID-19 
treatment. 
For the gene ontology (GO)7 analysis, the Fisher’s exact test, with the threshold p-value = 0.1, 
was used to identify the statistically activated GOs based on the up-regulated genes. Since there 
are many activated GOs, and some of them are semantically close and sharing the common set 
of genes, it is difficult to identify which are the most important GOs. To solve this challenge, we 
first manually removed many of activated GOs that are not related to biological signaling 
processes or general diseases. In addition, we defined the super-GOs, which are defined as sub-
groups of GOs that have similar or related biological processes. Specifically, after the calculation 
of GO-GO similarity using the semantic similarity8 (GOSemSim R package) between activated 
GOs, the affinity propagation clustering9 (APclustering) was used to divide the activated GOs into 
sub-groups (named super-GOs). Then the genes up-regulated within each super-GO were used 
as signatures to identify potential medications that can inhibit activation of the super-GOs. These 
gene signatures were fed into the connectivity map (CMAP)10,11 database to identify potential 
drugs. A gene set enrichment analysis (GSEA)12 was applied on the z-profiles (gene expression 
variation before and after treatment with 2,837 drugs and investigational agents) of 9 cells10,11 in 
the CMAP to identify gene set signature-specific inhibitory drugs. The top ranked FDA drugs, 
based on the average GSEA scores, that can potentially inhibit the up-regulated gene signatures 
associated with super-GOs were identified as potential candidates for COVID-1 treatment.  
 
3. Results 
3.1 Activated signaling pathways and associated inhibitory medications 
The KEGG signaling pathway analysis was conducted to identify the activated signaling pathways 
within the lung A549 cells after SARS-CoV-2 infection (see Fig. 1-Upper). As shown, the 
IRF7/IFR9, NFkB1, NFkB2, STAT1, MAPK3K8, MAPK8, MAPK14 related signaling pathways are 
the major activated transcription factors (TFs), which promotes the downstream activation of 
many signaling pathways including those mediated by CXCR6, CXCL1, CXCL2, CXCL3, CXCL10, 
and MYD88, CREBBP and JAK1, JAK2 and STAT signaling mechanisms. Also, the 
WNT4/WNT7A and SMAD signaling pathways are activated. Moreover, the PDGFB-EGFR and 
TUBB1C/2B/3 proliferation signaling.    
Based on drug-target interaction data derived from DrugBank, there are 220 drugs (71 drugs 
targeting on the PTGS2) targeting 97 genes on the signaling network (see supplementary Table 
S1). Chloroquine and hydroxychloroquine were found to inhibit MYD88 immune signaling. Also, 
acetylsalicylic acid, thalidomide, pranlukast, triflusal, glycyrrhizic acid and fish oil inhibit NFkB 
signaling, which was a potential signaling target for SARS14 treatment, and can potentially inhibit 
IRF7 activity. Thalidomide15 inhibiting NFkB and TNF was reported as potential treatment for 
COVID-19. Moreover, the tumor necrosis factor (TNF) is reported in Lancet16 to be an important 
therapeutic target for COVID-19. Also, JAK1/2 pathways are reported as important targets, and 
their inhibitors, ruxolitinib, tofacitinib, baricitinib and fostamatinib, could be effective for COVID-19 
treatment. Particularly, baricitinib, an arthritis drug, could help reduce the out-of-control immune 
response (https://www.wired.com/story/ai-uncovers-potential-treatment-covid-19-patients/, and  
  
 
 
Figure 1: (Upper) Activated signaling pathways (with 244 genes) within NHBE and also 
appeared in lung A549_ACE2 and CALU3 cells after SARS-CoV-2 infection. Red nodes are 
transcription factors (TFs); green - receptors; purple - ligands; orange - activated target genes 
of TFs; and cyan - the linking genes. (Lower) 220 drugs (cyan) (with 97 target genes) targeting 
on the activated signaling pathways. 
https://www.clinicaltrialsarena.com/news/eli-lilly-to-study-baricitinib-for-covid-19-treatment/), was 
reported in the Lancet17 as a COVID-19 suitable treatment. In addition, MAPK1, AKT and PRKCA 
inhibitors such as isoprenaline, arsenic trioxide, vitamin e, and midostaurin could be effective. The 
IL6R inhibitor tocilizumab was reported for COVID-19 treatment18, and another IL6R inhibitor, 
sarilumab, is being tested in clinical trials (ClinicalTrials.gov Identifier: NCT04327388). Moreover, 
STAT1 and IFANR1 are reported to be potential targets for COVID-19 treatment19.   
In addition, the medications used in global clinical trials were identified to compare with the 
drugs uncovered based on the signaling pathway analysis. Based on the dashboard of clinical 
trials for COVID-19 treatment, ~108 FDA approved drugs were reported from 1,132 clinical trials 
globally (see Table I). Among the 108 drugs, 31 of them are in the predicted drugs list. These 
drugs are: hydroxychloroquine, chloroquine, tocilizumab, sarilumab, canakinumab, ruxolitinib, 
oxygen, sirolimus, ibuprofen, anakinra, acalabrutinib, baricitinib, ibrutinib, lenalidomide, tirofiban, 
acetylsalicylicacid, simvastatin, siltuximab, bevacizumab, tinzaparin, naproxen, celecoxib,  
tofacitinib,  adalimumab,  thalidomide,  dalteparin,  nadroparin, minocycline, lithium,  indomethacin,  
and nintedanib. In summary, the predicted signaling network could be helpful to understand the 
molecular mechanisms within lung host cells after SARS-CoV-2 infection. Drugs targets on the 
signaling targets might be effective (some might also have harmful effects and cautions), and 
different targets can be potential synergistic drug combinations. However, the network analysis is 
still limited to understand the specific signaling pathways that are important for the viral 
proliferation. Also some immune signaling pathways should not the targets considering that they 
are important for viral inhibition. Thus, rigorous experimental validations are needed to validate 
these results, considering the limitation of pure computational data analysis based on the noisy 
and limited data. 
 
Table I: FDA approved drugs in clinical trials for COVID-19 treatment. 
zidovudine heparin deferoxamine verapamil mefloquine 
hydroxychloroquine linagliptin methyleneblue siltuximab dalteparin 
lopinavir telmisartan chlorpromazine defibrotide nadroparin 
tocilizumab anakinra lenalidomide bevacizumab iloprost 
sarilumab vitaminc methotrexate tinzaparin sofosbuvir 
atazanavir zinc tirofiban naproxen vitamina 
tranexamicacid almitrine clopidogrel ritonavir metformin 
alteplase sitagliptin acetylsalicylicacid tacrolimus berberine 
canakinumab ciclesonide fondaparinux celecoxib licorice 
ruxolitinib acalabrutinib ramipril tofacitinib bromhexine 
colchicine etoposide progesterone pirfenidone minocycline 
leflunomide ketamine captopril hydrogenperoxide lithium 
oxygen losartan eculizumab sildenafil formoterol 
sirolimus valsartan sevoflurane ixekizumab indomethacin 
povidone-iodine baricitinib nitazoxanide dexmedetomidine selenium 
fluvoxamine fluoxetine sargramostim lipoicacid nintedanib 
ibuprofen vitamind ribavirin tranilast spironolactone 
aviptadil bicalutamide nivolumab adalimumab imatinib 
doxycycline ivermectin melatonin thalidomide estradiol 
enoxaparin sodiumbicarbonate simvastatin fingolimod chloroquine 
prazosin ibrutinib dapagliflozin suramin  
isotretinoin levamisole amiodarone itraconazole  
 
 
3.2 Activated Gene Ontologies (GOs) 
Based on the fold change and p-value obtained from the DEseq2 analysis of NHBE, A549_ACE2, 
and CALU-3 cells before and after the viral infection, the up-regulated genes in each cell were 
identified respectively. Specifically, for the NHBE cells, 558 genes had a statistically significant 
increase in fold-change >= 1.25 and p_value <= 0.05. For the A549_ACE2 cells, 1335 up-
regulated genes were identified with the fold-change >= 2.0 and p_value <= 0.05. For the CALU-
3 cells, 1335 up-regulated genes were identified with the fold-change >= 2.0 and p_value <= 0.05. 
Based on the three up-regulated gene sets, the activated GOs with enriched genes in the 
three gene sets were identified respectively with a p-value <= 0.05 (obtained from the Fisher’s 
exact test), and the number of genes in GOs between 10 and 1000. Then the common activated 
GOs between NHBE and A549_ACE2, and between NHBE and CALU-3 were unified. After 
empirically removing the unrelated and general GOs, 73 GOs were kept. Then the clustering 
analysis was employed to divide the activated GOs into 5 sub-groups (named super-GOs). 
Among the 73 GOs, 212 up-regulated genes were kept. Fig. 2 shows the network of the 212 up-
regulated genes, 73 activated GOs and 5 super-GOs. Genes associated with the GOs in each 
super-GO are collected as gene set signatures for drug discovery analysis. In addition to the viral 
process related signaling, the GO analysis identified many potential viral infections related 
signaling pathways, e.g., MAPK, JNK, STAT, ERK1/2, MYD88 and Toll like receptor signaling 
pathways. The results are consistent and complement with the KEGG signaling pathway analysis.  
 
 
3.3 Reposition drugs inhibiting individual super-GOs 
The gene signatures in each of 5 super-GO clusters were used as the query input of the CMAP 
database to identify drugs capable of inhibiting the associated genetic pathways. Specifically, 
there are 255 drugs appeared in the top 100 drugs in one of the 5 super-GOs. There are 26 
common drugs among the drugs derived based on signaling network analysis and super-GO 
analysis (see Table II). The top 65 drugs were selected based on if their frequency (>= 3) 
 
Figure 2: Network of 212 up-regulated genes (cyan color) 
in lung NHBE, A549_ACE2 and CALU-3 cells after SARS-CoV-2. There are 73 activated gene 
ontologies (GOs; red color), and 5 super-GOs (clusters of GOs; purple color). The node size of 
genes and GOs is proportional to the fold change and negative log2 p-values respectively.   
appeared in the top 100 drugs of each of the 5 super-GOs (see Fig. 3 and Table III). In Table III, 
some frequency values are greater than 9, as some drugs were tested in CMAP at different doses. 
Table VI lists all the excluded drugs (not in the top 66 drugs) for each super-GO.   
 
Table II: Twenty-seven common FDA approved drugs derived from signaling network analysis 
and super-GO analysis. 
caffeine lenalidomide naproxen sunitinib talniflumate 
lovastatin dextromethorphan phenylbutazone resveratrol fostamatinib 
lidocaine diclofenac thalidomide nimesulide chloroquine 
gefitinib chloroquine naloxone pazopanib 
 
sorafenib simvastatin dasatinib tofacitinib 
 
nabumetone imiquimod lapatinib afatinib 
 
 
Table III: Top 65 drugs frequently appeared in the top-ranked drugs of 5 super-GOs.  
Name Freq Name Freq Name Freq Name Freq Name Freq 
dexamethasone 17 azithromycin 4 norepinephrine 4 doconexent 3 nitrendipine 3 
hydrocortisone 9 carbetocin 4 promazine 4 efavirenz 3 olanzapine 3 
atorvastatin 7 deferiprone 4 rilmenidine 4 estrone 3 phensuximide 3 
fenofibrate 5 diazepam 4 simvastatin 4 fluticasone 3 piperacillin 3 
flupirtine 5 doxycycline 4 verapamil 4 formoterol 3 pirfenidone 3 
palonosetron 5 enalapril 4 ziprasidone 4 fostamatinib 3 pirlindole 3 
parthenolide 5 gefitinib 4 amcinonide 3 lapatinib 3 pravastatin 3 
pindolol 5 halcinonide 4 amoxapine 3 lenalidomide 3 quinidine 3 
sitagliptin 5 iloperidone 4 amylocaine 3 mepyramine 3 rosuvastatin 3 
testosterone 5 lovastatin 4 budesonide 3 naftifine 3 scopolamine 3 
triamcinolone 5 melperone 4 dicloxacillin 3 naloxone 3 temozolomide 3 
trimethobenzamide 5 memantine 4 diethylstilbestrol 3 naltrexone 3 thalidomide 3 
vemurafenib 5 mestranol 4 diltiazem 3 nifedipine 3 tocainide 3 
 
 
To validate the prediction, the related literatures were manual searched that related to the 
drug and COVID-19, or coronavirus. The ‘dexamethasone’ (glucocorticoid receptor agonist, 
corticosteroid agonist, immunosuppressant) (frequency = 17) (ClinicalTrials.gov Identifier: 
NCT04327401) and ‘hydrocortisone’ (corticosteroid agonist, glucocorticoid receptor agonist, 
immunosuppressant, interleukin receptor antagonist) (frequency = 9) were reported to be related 
to COVID-19 treatment. Moreover, the lopinavir (HIV protease inhibitor) was included in the list of 
drugs being tested for coronavirus treatment. We further compared the GO analysis derived drugs 
with the clinical trials drugs, and 13 drugs were in both the prediction list and the clinical trial 
reports. The 13 drugs are: lopinavir, leflunomide, doxycycline, sitagliptin, lenalidomide, 
simvastatin, verapamil, naproxen, tacrolimus, tofacitinib, pirfenidone, thalidomide and formoterol. 
Moreover, 5 drugs appeared in the predictions derived from signaling network analysis, GO 
analysis and clinical trials: lenalidomide, simvastatin, naproxen, tofacitinib, thalidomide. Again, 
the prediction based on pure data analysis is limited due to the quality of the gene expression 
data and the general GO terms. Some of these drugs might have harmful effects and cautions, 
and thus, rigorous clinical trials and experimental validations are needed to validate these results. 
 
 
 
 
Figure 3: The 65 drugs inhibiting the up-regulated genes in 5 super-GOs.    
4. Discussion and Conclusion 
Currently, there is no effective vaccine or approved therapy for the treatment COVID-19, through 
rapid developments are occurring and being translated into clinical use. As the disease continues 
to spread, it is becoming increasingly important to develop a treatment modality in the most time-
efficient manner. One such approach is to use genetic information to inform the repurposing of 
available medications. This preliminary and exploratory analysis uses upregulated gene 
expression profiles from human lung host cells infected with the SARS-CoV-2. Some potentially 
important targets and a signaling network, as well as a set of GOs activated within lung cells after 
viral infection were identified. Moreover, a set of drugs registered for COVID-19 treatment globally 
were also identified by this analysis. It can be helpful to facilitate the design of future clinical trials 
for the COVID-19 treatment. However, this analysis is based on pure computational data analysis, 
and rigorous clinical trials and experimental validations are needed to validate these results. 
Some of these drugs might have harmful effects and cautions, even they were used in some 
research or clinical trials.   
Despite these interesting preliminary results, this exploratory computational study still has 
significant limitations. First, the genetic data are derived from an in vitro analysis and will inevitably 
have a gene expression profile different from an in vivo epithelial, which may be further modified 
on a person-to-person basis. Second, the signaling network analysis models should be improved 
by integrating the KEGG signaling pathways with the GOs (to include more genes) and with more 
omics data, e.g., RNA-seq and proteomics available from lung cells or patients’ lung tissues. In 
the future work, we will investigate these challenges. Third, the unbiased list of medications 
generated and presented was not filtered by route of administration or clinical applicability. For 
instance, the immune dampening chemotherapeutic agent docetaxel was identified, but would 
likely not be administered to an infected patient due to concern for augmenting viral replication. 
Fourth, many medications do not have a direct effect that is dependent on modifying gene 
expression and could have many downstream, off target effects which could negate the clinical 
utility of such a therapy. Therefore, further pipelines and additional information are needed to 
analyze the potential effects of these medications, and to continue developing this computational 
approach to medication repurposing.  
 
 
 
Table V: Information on the 66 drugs frequently appearing in the top 100 ranked drugs of each of 
9 super-GOs. 
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 Tables 
Table S1: 220 drugs and targets on the potential dysfunctional signaling network of COVID19.  
 
Gene 
Symbol Drug Name 
Gene 
Symbol Drug Name 
Gene 
Symbol Drug Name 
Gene 
Symbol Drug Name 
BCL2L1 isosorbide IL1A rilonacept NCF1 dextromethorphan RELA dimethyl fumarate 
CASP1 minocycline IRAK4 fostamatinib NCF2 dextromethorphan RIPK1 fostamatinib 
CSNK2A2 fostamatinib ITGB2 simvastatin NFATC1 pseudoephedrine RIPK2 fostamatinib 
CTNNB1 urea LEF1 etacrynic acid NFKBIA acetylsalicylic acid RPS6KA4 flavin mononucleotide 
CXCL10 clove oil LTA etanercept NOD2 mifamurtide SGK1 flavin mononucleotide 
CXCL12 tinzaparin MAP2K3 fostamatinib NOX1 oxygen STAT5B dasatinib 
ERN1 fostamatinib MAP3K11 fostamatinib PAK1 fostamatinib SYK fostamatinib 
FLNA artenimol MAP3K13 fostamatinib PAK4 fostamatinib TAB1 manganese 
GJA1 carvedilol MAP4K4 fostamatinib PKN1 fostamatinib TBK1 fostamatinib 
HIF1A carvedilol MAPK11 regorafenib POMC loperamide TEC fostamatinib 
IFNGR1 interferon gamma-1b MAPK13 fostamatinib PTK2 fostamatinib TLR8 imiquimod 
IKBKE fostamatinib MYC nadroparin RAC2 dextromethorphan TNFRSF1A tasonermin 
ZAP70 fostamatinib CSNK2A1 resveratrol, fostamatinib FYN dasatinib, fostamatinib IL1R1 anakinra, foreskin fibroblast (neonatal) 
AKT1 arsenic trioxide, resveratrol FOS pseudoephedrine, nadroparin GSK3B lithium, fostamatinib IL6R tocilizumab, sarilumab 
ITK pazopanib, fostamatinib MAPK14 dasatinib, fostamatinib PIK3CA caffeine, copanlisib RAC1 
dextromethorphan, 
azathioprine 
MAP3K1 binimetinib, fostamatinib PDPK1 celecoxib, fostamatinib PRKCI tamoxifen, fostamatinib ROCK1 ripasudil, netarsudil 
TLR2 
lyme disease 
vaccine 
(recombinant 
ospa), tuberculin 
purified protein 
derivative 
TNFRSF1B etanercept, tasonermin MAP2K1 cobimetinib, bosutinib, trametinib,  BTK 
dasatinib, ibrutinib, 
acalabrutinib, fostamatinib 
TLR7 
imiquimod, 
hydroxychloroquin
e 
ICAM1 natalizumab, hyaluronic acid, nafamostat,  MAPK1 
isoprenaline, arsenic 
trioxide, turpentine,  CHUK 
aminosalicylic acid, 
mesalazine, sulfasalazine, 
acetylcysteine 
TLR9 
chloroquine, 
hydroxychloroquin
e 
LY96 morphine, methadone, lauric acid,  VCAM1 
ethanol, carvedilol, clove 
oil,  JAK1 
ruxolitinib, tofacitinib, 
baricitinib, fostamatinib 
JAK2 
ruxolitinib, 
tofacitinib, 
baricitinib, 
fostamatinib 
TLR4 naloxone, lauric acid, papain, mifamurtide ITGAL 
efalizumab, antithymocyte 
immunoglobulin (rabbit), 
lovastatin, simvastatin, 
lifitegrast,  
IL1B 
minocycline, gallium nitrate, 
canakinumab, rilonacept, 
foreskin keratinocyte 
(neonatal), binimetinib 
JUN 
vinblastine, 
pseudoephedrine, 
irbesartan, arsenic 
trioxide 
EDNRA 
bosentan, acetylsalicylic acid, 
sitaxentan, ambrisentan, 
macitentan,  
ITGB3 
abciximab, eptifibatide, 
antithymocyte 
immunoglobulin (rabbit), 
tirofiban, resveratrol,  
IL6 
ginseng, siltuximab, 
polaprezinc, foreskin 
fibroblast (neonatal), foreskin 
keratinocyte (neonatal), 
binimetinib 
NFKB2 
acetylsalicylic acid, 
glucosamine, 
glycyrrhizic acid, 
fish oil 
IFNG 
olsalazine, glucosamine, 
apremilast, foreskin fibroblast 
(neonatal), foreskin 
keratinocyte (neonatal),  
MTOR 
pimecrolimus, sirolimus, 
everolimus, temsirolimus, 
fostamatinib,  
NFKB1 
acetylsalicylic acid, 
thalidomide, pranlukast, 
triflusal, glycyrrhizic acid, fish 
oil 
SRC dasatinib, citric acid, bosutinib, ponatinib, nintedanib, fostamatinib 
IKBKB mesalazine, sulfasalazine, acetylsalicylic acid, auranofin, arsenic trioxide, acetylcysteine, fostamatinib,  
PRKCA phosphatidyl serine, vitamin e, tamoxifen, ingenol mebutate, midostaurin, alpha-tocopherol succinate, d-alpha-tocopherol acetate,  
IFNAR1 peginterferon alfa-2a, interferon alfa-n1, interferon alfa-n3, peginterferon alfa-2b, interferon alfa-2a,  recombinant, interferon beta-1a, interferon beta-1b, interferon alfacon-1, interferon alfa-2b,  recombinant, natural alpha interferon 
KDR sorafenib, sunitinib, ramucirumab, pazopanib, midostaurin, axitinib, cabozantinib, regorafenib, ponatinib, lenvatinib, nintedanib, fostamatinib 
VEGFA bevacizumab, minocycline, gliclazide, carvedilol, ranibizumab, pidolic acid, tromethamine, vandetanib, dalteparin, aflibercept, chondroitin sulfate, foreskin keratinocyte (neonatal) 
EGFR cetuximab, trastuzumab, lidocaine, gefitinib, erlotinib, lapatinib, panitumumab, vandetanib, afatinib, osimertinib, necitumumab, foreskin keratinocyte (neonatal), icotinib, neratinib, fostamatinib, brigatinib, olmutinib,  
TNF etanercept, adalimumab, infliximab, chloroquine, epinephrine, pseudoephedrine, thalidomide, glucosamine, clenbuterol, pranlukast, amrinone, isopropyl alcohol, apremilast, golimumab, certolizumab pegol, pomalidomide, polaprezinc, foreskin fibroblast (neonatal), foreskin keratinocyte (neonatal), binimetinib, glycyrrhizic acid,  
PTGS2 
dihomo-gamma-linolenic acid, icosapent, adapalene, aminosalicylic acid, mesalazine, acetaminophen, indomethacin, nabumetone, ketorolac, tenoxicam, lenalidomide, 
celecoxib, tolmetin, rofecoxib, piroxicam, fenoprofen, valdecoxib, diclofenac, sulindac, flurbiprofen, etodolac, mefenamic acid, naproxen, sulfasalazine, phenylbutazone, 
meloxicam, carprofen, diflunisal, suprofen, salicylic acid, meclofenamic acid, acetylsalicylic acid, bromfenac, oxaprozin, ketoprofen, balsalazide, thalidomide, ibuprofen, 
lumiracoxib, magnesium salicylate, salsalate, choline magnesium trisalicylate, ginseng, antrafenine, antipyrine, tiaprofenic acid, etoricoxib, resveratrol, niflumic acid, 
nimesulide, lornoxicam, aceclofenac, nepafenac, parecoxib, pomalidomide, loxoprofen, dexibuprofen, dexketoprofen, tolfenamic acid, morniflumate, propacetamol, 
talniflumate, phenyl salicylate, trolamine salicylate, menthyl salicylate, glycol salicylate, dipyrithione, alclofenac, bufexamac, acemetacin, fish oil,  
 
 
 
 
 
